Biofrontera AG (0DOL.L) reported Q4 2024 revenue of USD 12.55 million, marking YoY growth of 18.5% and QoQ growth of 39.3% against a backdrop of ongoing profitability challenges. Gross profit totaled USD 7.86 million, yielding a gross margin of 62.6%, underscoring a stable product-level margin despite a lean cost structure. However, the company posted an operating loss of USD 1.71 million and a net loss of USD 1.40 million for the quarter, with EBITDA negative USD 1.12 million. The discrepancy between reported EPS (USD 2.97) and the net loss highlights potential data incongruities in per-share accounting or share count assumptions in the quarter, warranting clarification in subsequent filings. Cash flow remained negative from operating activities (USD -1.02 million) but the balance sheet shows improving liquidity with USD 6.11 million in cash and equivalents at period end and a net cash position of roughly USD -0.98 million in net debt, aided by USD 4.05 million of financing activity net inflow during the quarter.
Key drivers for the quarter include continued strength of the core dermatology portfolio (Ameluz and BF-RhodoLED family) and the potential upside from ongoing commercialization efforts in the US and Europe. Management commentary (not provided in the supplied transcript) would be required to validate near-term guidance and quarterly cadence. The balance sheet remains modestly leveraged with total liabilities of USD 17.67 million and stockholders’ equity of USD 4.43 million, and liquidity metrics point to a conservative runway absent stronger operating cash flow. Overall, Biofrontera enters 2025 with a credible gross margin foundation and a cash runway that could support selective investments in growth initiatives, but the company needs to convert top-line momentum into sustained profitability to meaningfully alter its earnings trajectory.